Aug 8, 2018
NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies,
seen from United States
seen from Canada
seen from Martinique
seen from Germany
seen from China
seen from Türkiye
seen from Hong Kong SAR China
seen from Argentina
seen from China
seen from United States
seen from Canada
seen from Türkiye
seen from China
seen from United States
seen from Germany
seen from China
seen from Canada
seen from United Kingdom
seen from China
seen from United States
NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies,
Analysts Predict Upside for NeoGenomics, Inc. (Nasdaq:NEO), Finishing At $13.84
Analysts Predict Upside for NeoGenomics, Inc. (Nasdaq:NEO), Finishing At $13.84
NeoGenomics, Inc. (Nasdaq:NEO)
August 7th, 2018
NeoGenomics, Inc. fell $1.03 Sunday which equals a 6.93% drop, closing at $13.84. (more…)
View On WordPress
Breaking 52 Week High, NeoGenomics, Inc. (Nasdaq:NEO) Settle At $14.25
Breaking 52 Week High, NeoGenomics, Inc. (Nasdaq:NEO) Settle At $14.25
NeoGenomics, Inc. (Nasdaq:NEO)
July 10th, 2018
With markets going up NeoGenomics, Inc. finished up $0.22 Sunday, up 1.57%, closing at $14.25. Furthermore it hit a new 52 week high of $14.35. The stock continues to trade well at 101% of its 52 week low of $7.08. It’s expected that NeoGenomics, Inc. will report earnings within the next couple of weeks. (more…)
View On WordPress
(Nasdaq:NEO) NeoGenomics, Inc. Breaks 52 Week High Record Of $13.61
(Nasdaq:NEO) NeoGenomics, Inc. Breaks 52 Week High Record Of $13.61
NeoGenomics, Inc. (Nasdaq:NEO)
June 21st, 2018
NeoGenomics, Inc. closed Wednesday up 0.60%, a $0.08 increase to close on $13.47. In addition it hit a new 52 week high of $13.61. While it is positive news the stock ended higher, the trading volumes were only 0.00% of normal which could be an indication of investor uncertainty.
NEO outperformed the rest of the Healthcare sector which went up…
View On WordPress
(Nasdaq:NEO) NeoGenomics, Inc. Sets 52 Week High Record
(Nasdaq:NEO) NeoGenomics, Inc. Sets 52 Week High Record
NeoGenomics, Inc. (Nasdaq:NEO)
June 20th, 2018
Amidst falling markets NeoGenomics, Inc. rose $0.39 Tuesday, up 3.00%, closing at $13.39. In addition it hit a new 52 week high of $13.40. While it is positive news the stock ended higher, the trading volumes were only 0.00% of normal which could be an indication of investor uncertainty.
NEO outperformed the rest of the Healthcare sector which…
View On WordPress
Hitting 52 Week High, NeoGenomics, Inc. (Nasdaq:NEO) Close At $12.96
Hitting 52 Week High, NeoGenomics, Inc. (Nasdaq:NEO) Close At $12.96
NeoGenomics, Inc. (Nasdaq:NEO)
June 11th, 2018
With markets going up NeoGenomics, Inc. went up $0.20 Tuesday, a 1.57% increase, closing at $12.96. In addition it hit a new 52 week high of $12.99.
NEO outperformed the rest of the Healthcare sector which went up 0.10% today.
Analysis results from 6 analysts suggest that NeoGenomics, Inc. might decline somewhat (-4.62%), while Finboxhas…
View On WordPress
Hitting 52 Week High, NeoGenomics, Inc. (Nasdaq:NEO) Ends The Day At $12.54
Hitting 52 Week High, NeoGenomics, Inc. (Nasdaq:NEO) Ends The Day At $12.54
NeoGenomics, Inc. (Nasdaq:NEO)
June 1st, 2018
Amidst rising markets NeoGenomics, Inc. closed Saturday up 8.10%, a $0.94 increase to close on $12.54. In addition it hit a new 52 week high of $12.95. In addition to finishing higher, trading volumes were solid at 286% of normal which can indicate investors see opportunities.
NEO outperformed the rest of the Healthcare sector which went up…
View On WordPress
NeoGenomics to Pay $275M for Clarient
NeoGenomics to Pay $275M for Clarient
More on this recent news to follow on thoughts about implications for pathology market as a whole and digital pathology (including GE-Omnyx). GE paid $587 million for Clarient in an announcement 5 years ago today.
NeoGenomics, a biotech company specializing in genomic cancer diagnostics, has announced the acquisition of Clarient, a unit of General Electric (GE) Healthcare’s Life Sciences…
View On WordPress